Evommune (EVMN) Treasury Shares (2024 - 2025)
Evommune's (EVMN) quarterly Treasury Shares came in at $328318.0 in Q4 2025, down 99.72% year-on-year from $116.7 million in Q4 2024, and down 99.79% on a QoQ basis from $157.7 million in Q3 2025.
Evommune (EVMN) Treasury Shares (2024 - 2025) Analysis & Trends
Evommune (EVMN) has 2 years of Treasury Shares data on file, last reported at $328318.0 in Q4 2025.
- On a quarterly basis, Treasury Shares fell 99.72% year-over-year to $328318.0 in Q4 2025; TTM through Dec 2025 was $328318.0, a 99.72% decrease from a year earlier, with the FY2025 full-year figure at $328318.0, down 99.72% from the prior year.
- Treasury Shares for Q4 2025 stood at $328318.0, down from $157.7 million in the prior quarter.
- Over the last five years, Treasury Shares for EVMN reached as high as $157.7 million in Q3 2025 and fell as low as $328318.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 265,401.92 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 19.41 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 5.14 Mn |
| 10 | Evommune | 381.48 Mn | 170.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 328,318.00 |
| Dec 31, 2025 | 328,318.00 |
| Sep 30, 2025 | 157.66 Mn |
| Sep 30, 2025 | 157.66 Mn |
| Mar 31, 2025 | 116.72 Mn |
| Mar 31, 2025 | 116.72 Mn |
| Dec 31, 2024 | 116.72 Mn |
| Dec 31, 2024 | 116.72 Mn |
| Sep 30, 2024 | 85.22 Mn |
| Sep 30, 2024 | 85.22 Mn |